Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma

Immune checkpoint inhibitors (CPIs), including pembrolizumab, are becoming common oncological treatments. CPIs have been associated with a significant risk of developing immune-related adverse events (irAEs), such as nephritis and interstitial nephritis. However, the occurrence of glomerulonephritis...

Descripción completa

Detalles Bibliográficos
Autores principales: Oki, Rikako, Hirakawa, Yosuke, Kimura, Hitomi, Honda, Kenjiro, Hinata, Munetoshi, Abe, Hiroyuki, Domoto, Yukako, Tanaka, Goh, Nagase, Takahide, Nangaku, Masaomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184094/
https://www.ncbi.nlm.nih.gov/pubmed/31813918
http://dx.doi.org/10.2169/internalmedicine.3928-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184094/
https://www.ncbi.nlm.nih.gov/pubmed/31813918
http://dx.doi.org/10.2169/internalmedicine.3928-19

Ejemplares similares